Download PDF
Semin Musculoskelet Radiol 2007; 11(3): 231-239
DOI: 10.1055/s-2008-1038312
© Thieme Medical Publishers

Myeloma Update

Michael E. Mulligan1
  • 1Department of Radiology, University of Maryland Medical Center, Baltimore, Maryland
Further Information

Publication History

Publication Date:
07 February 2008 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Myeloma is the most common primary bone malignancy and one of the most common hematologic malignancies. Research on myeloma constantly produces new information on genetic factors, imaging techniques, and treatment complications among others that is of use to patients, referring physicians, and radiologists. This update emphasizes new developments regarding imaging techniques for diagnosis, staging, and follow-up of myeloma patients. Advances in whole body radiography, whole body computed tomography, whole body magnetic resonance imaging, and whole body nuclear techniques (including sestamibi and positron emission tomography) are discussed.

KEYWORDS

Myeloma - imaging - computed tomography - magnetic resonance imaging - positron emission tomography

REFERENCES

  • 1 Alexander D D, Mink P J, Adami H O et al.. Multiple myeloma: a review of the epidemiologic literature.  Int J Cancer. 2007;  120(Suppl 12) 40-61
    CrossrefPubMedGoogle Scholar
  • 2 Corre J, Mahtouk K, Attal M et al.. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.  Leukemia. 2007;  21 1079-1088
    PubMedGoogle Scholar
  • 3 Shaughnessy J D, Haessler J, van Rhee F et al.. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.  Br J Haematol. 2007;  137 530-536
    CrossrefPubMedGoogle Scholar
  • 4 Tinguely M, Jenni B, Reineke T et al.. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.  Am J Surg Pathol. 2007;  31 690-696
    PubMedGoogle Scholar
  • 5 International Myeloma Working Group . Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders.  Br J Haematol. 2003;  121 749-757
    CrossrefPubMedGoogle Scholar
  • 6 Greipp P R, San Miguel J, Durie B G et al.. International staging system for multiple myeloma.  J Clin Oncol. 2005;  23 3412-3420
    CrossrefPubMedGoogle Scholar
  • 7 Mulligan M E. Imaging techniques used in the diagnosis, staging, and follow-up of patients with myeloma.  Acta Radiol. 2005;  46 716-724
    CrossrefPubMedGoogle Scholar
  • 8 Durie B G, Salmon S E. A clinical staging system for multiple myeloma.  Cancer. 1975;  36 842-854
    CrossrefPubMedGoogle Scholar
  • 9 Durie B G, Kyle R A, Belch A et al.. Myeloma management guidelines: a consensus report from the scientific advisors of the international myeloma foundation.  Hematol J. 2003;  4 379-398
    CrossrefPubMedGoogle Scholar
  • 10 Moulopoulos L A, Maris T G, Papanikolaou N, Panagi G, Vlahos L, Dimopoulos M A. Detection of malignant bone marrow involvement with dynamic contrast-enhanced magnetic resonance imaging.  Ann Oncol. 2003;  14 152-158
    CrossrefPubMedGoogle Scholar
  • 11 Walker R, Barlogie B, Haessler J et al.. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.  J Clin Oncol. 2007;  25 1121-1128
    CrossrefPubMedGoogle Scholar
  • 12 Durie B G, Waxman A D, D'Agnolo A, Williams C M. Whole-body 18F-FDG PET identifies high-risk myeloma.  J Nucl Med. 2002;  43 1457-1463
    PubMedGoogle Scholar
  • 13 Gertz M A. Relevant prognostic features of multiple myeloma and the new international staging system.  Leuk Lymphoma. 2007;  48 458-468
    PubMedGoogle Scholar
  • 14 Moulopoulos L A, Dimopoulos M A, Weber D, Fuller L, Libshitz H I, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone.  J Clin Oncol. 1993;  11 1311-1315
    PubMedGoogle Scholar
  • 15 Mulligan M E. Myeloma and lymphoma.  Semin Musculoskelet Radiol. 2000;  4 127-135
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Tsang R W, Gospodarowicz M K, Pintilie M et al.. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome.  Int J Radiat Oncol Biol Phys. 2001;  50 113-120
    CrossrefPubMedGoogle Scholar
  • 17 Ooi G C, Chim J C, Au W Y, Khong P L. Radiologic manifestations of primary solitary extramedullary and multiple solitary plasmacytomas.  AJR Am J Roentgenol. 2006;  186 821-827
    CrossrefPubMedGoogle Scholar
  • 18 Weber D M, Dimopoulos M A, Moulopoulos L A, Delasalle K B, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma.  Br J Haematol. 1997;  97 810-814
    PubMedGoogle Scholar
  • 19 Blade J, Rosinol L. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.  Curr Treat Options Oncol. 2006;  7 237-245
    CrossrefPubMedGoogle Scholar
  • 20 Mulligan M E, Badros A Z. PET/CT and MR imaging in myeloma.  Skeletal Radiol. 2007;  36 5-16
    PubMedGoogle Scholar
  • 21 Dispenzieri A. POEMS syndrome.  Hematol Am Soc Hematol Educ Program. 2005;  360-367
    PubMedGoogle Scholar
  • 22 Horger M, Claussen C, Bross-Bach U et al.. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography.  Eur J Radiol. 2005;  54 289-297
    CrossrefPubMedGoogle Scholar
  • 23 Mahnken A H, Wildberger J E, Gehbauer G et al.. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography.  AJR Am J Roentgenol. 2002;  178 1429-1436
    CrossrefPubMedGoogle Scholar
  • 24 Durie B G. The role of anatomic and functional staging in myeloma: description of Durie/Salmon PLUS staging system.  Eur J Cancer. 2006;  42 1539-1543
    CrossrefPubMedGoogle Scholar
  • 25 Hillengass J, Wasser K, Delorme S et al.. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.  Clin Cancer Res. 2007;  13 475-481
    CrossrefPubMedGoogle Scholar
  • 26 Lecouvet F E, Dechambre S, Malghem J, Ferrant A, Vande Berg B C, Maldague B. Bone marrow transplantation in patients with multiple myeloma: prognostic significance of MR imaging.  AJR Am J Roentgenol. 2001;  176 91-96
    CrossrefPubMedGoogle Scholar
  • 27 Breyer R J, Mulligan M E, Smith S E, Line B R, Badros A Z. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma.  Skeletal Radiol. 2006;  35 632-640
    CrossrefPubMedGoogle Scholar
  • 28 Bredella M A, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma.  AJR Am J Roentgenol. 2005;  184 1199-1204
    CrossrefPubMedGoogle Scholar
  • 29 Agool A, Schot B, Jager P, Vellenga E. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment.  J Nucl Med. 2006;  47 1592-1598
    PubMedGoogle Scholar
  • 30 Dankerl A, Liebisch P, Glatting G et al.. Multiple myeloma: molecular imaging with 11C-methionine PET/CT-initial experience.  Radiology. 2007;  242 498-508
    PubMedGoogle Scholar
  • 31 Nanni C, Zamagni E, Cavo M et al.. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.  World J Surg Oncol. 2007;  5 68-75
    CrossrefPubMedGoogle Scholar
  • 32 Mele A, Offidani M, Visani G et al.. Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans.  Br J Haematol. 2007;  136 729-735
    CrossrefPubMedGoogle Scholar
  • 33 Durie B G, Harousseau J L, Miguel J et al.. International uniform response criteria for multiple myeloma.  Leukemia. 2006;  20 1467-1473
    CrossrefPubMedGoogle Scholar
  • 34 Badros A, Weikel D, Salama A et al.. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.  J Clin Oncol. 2006;  24 945-952
    CrossrefPubMedGoogle Scholar
  • 35 Lacy M Q, Dispenzieri A, Gertz M A et al.. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma.  Mayo Clin Proc. 2006;  81 1047-1053
    PubMedGoogle Scholar

Michael E MulliganM.D. 

Department of Radiology, University of Maryland Medical Center

22 S. Greene St., Baltimore, MD 21201

Email: mmulligan@umm.edu

      >